Cool Company Ltd. – Mandatory Notification Of Trade
EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 17 June 2022 acquired 98,766 shares in the Company at an average price of NOK 87.42 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,199,264 shares in the Company, equivalent to 37.99% of the Company’s shares.
Please see attached notification form in accordance with the Market Abuse Regulation article 19.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Recor Medical Announces First Cases of Paradise Ultrasound Renal Denervation Therapy in the United Arab Emirates18.4.2024 17:00:00 CEST | Press release
l Qassimi Hospital Sharjah becomes first in the Middle East to treat patients with innovative new device-based option to help reduce blood pressure. Palo Alto, CA, April 18, 2024 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), announce the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension in the United Arab Emirates (UAE). Three cases were performed at Al Qassimi Hospital in Sharjah by Dr. Arif Al Nooryani and Dr. Loai Mousa as second operator. The Paradise uRDN system is a first-of-its-kind ultrasound-based renal denervation (RDN) technology designed to lower blood pressure by denervating overactive sympathetic nerves surrounding the renal arteries. Paradise uRDN delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through the main renal arteries to the surrounding nerves. The Paradise cathete
Q1, 202418.4.2024 16:56:35 CEST | Press release
To Nasdaq OMX Copenhagen A/S Public announcement no. 556 April 18th, 2024 ECONOMIC KEY FIGURES FOR GLUNZ & JENSEN HOLDING A/S Q1 2024 The Q1, 2024 (January through March 2024) of the fiscal year was reviewed and approved by the Board of Directors. The Board of Directors announces the following consolidated financial statement year to date (YTD) for Q1 (January through March) of 2024. Highlights for the Q1 result for the fiscal year 2024: The revenue for YTD Q1, 2024 amounted to DKK 31.1 million (2023: DKK 40.5 million). EBITDA for the period was DKK 2.6 million (2023: DKK 6.4 million). Profit before tax for the period was DKK 1.0 million (2023: DKK 4.9 million). In the previous year (2023), Glunz & Jensen delivered a particularly strong Q1. Overall, the Q1, 2024 came out with better-than-expected revenue figures in the offset and flexo solvent segments, whereas the thermal segment showed a week demand. For further information please contact: CEO Henrik Blegvad Funk: phone +45 21 39 05
CONSTITUENT MEETING OF HONKARAKENNE'S BOARD OF DIRECTORS AND COMMITEES18.4.2024 16:45:00 CEST | Press release
HONKARAKENNE OYJ Stock Exchange Release 18 April 2024 at 17:45 CONSTITUENT MEETING OF HONKARAKENNE’S BOARD OF DIRECTORS AND COMMITTEES Honkarakenne Oyj’s Annual General Meeting held on Thursday 18 April 2024 in Honkarakenne’s Tuusula office at Lahdentie 870, Tuusula, Finland. The Annual General Meeting elected the following persons to the Board of Directors: Arto Halonen, Timo Kohtamäki, Maria Ristola, Kari Saarelainen and Antti Tiitola. The Board of Directors convened for its constituent meeting and appointed Timo Kohtamäki as Chairman of the Board and Maria Ristola as Vice Chairman of the Board. At the same board meeting Board of Directors decided not to set up any committees. HONKARAKENNE OYJ Marko Saarelainen President and CEO Further information: Marko Saarelainen, President and CEO, tel. +358 40 542 0254, marko.saarelainen@honka.com or Maarit Jylhä, CFO, tel. +358 40 594 4099, Maarit.jylha@honka.com DISTRIBUTION Nasdaq Helsinki Ltd Key media Financial Supervisory Authority www.ho
DECISIONS MADE BY HONKARAKENNE OYJ'S ANNUAL GENERAL MEETING18.4.2024 16:30:00 CEST | Press release
HONKARAKENNE OYJ Stock Exchange Release 18 April 2024 at 17:30 DECISIONS MADE BY HONKARAKENNE OYJ’S ANNUAL GENERAL MEETING Honkarakenne Oyj’s Annual General Meeting was held on Thursday, 18 April 2023 in Honkarakenne’s Tuusula office at Lahdentie 870, Tuusula, Finland. The General Meeting adopted the financial statements, approved the remuneration report, and granted discharge from liability for 2023 to the members of the Board of Directors and the President and CEO. Payment of dividends The Annual General Meeting decided that no dividend be paid for the financial year ended 31 December 2023. The Board of Directors decided that repayment of capital of EUR 0.09 per share to be distributed from the invested unrestricted equity fund as distribution of funds to shareholders. The repayment of capital will be paid to shareholders who, on the record date of the dividend payment, 22 April 2024, are registered in the company’s shareholders' register maintained by Euroclear Finland Ltd. The paym
Stock Exchange Release Dovre Guidance For Year 202418.4.2024 16:00:00 CEST | Press release
Dovre Group Plc Stock Exchange Release April 18, 2024, at 5.00 pm DOVRE GROUP PLC OUTLOOK FOR YEAR 2024 In 2024 our revenue is expected to be in the range of 185 - 210 MEUR and the Operating Profit (EBIT) is expected to be in the range of 2 - 4 MEUR. The lower than 2023 EBIT is due to a significant one-time write-down (approx. 6 million euros) of a single renewable project in Q1. The project was technically successful but exceeded the cost budget considerably. Corrective actions have been taken and Suvic expects the remainder of the 2024 to clearly exceed the comparison period of 2023 in both revenue and EBIT. Dovre`s Project personnel and Consulting business areas are expected to decline in both revenue and EBIT compared to 2023 due to the completion of a major project in Canada and somewhat slower activity in the Norwegian public sector. For further information: Dovre Group Plc Arve Jensen CEO Tel. +47 90 60 78 11 arve.jensen@dovregroup.com Hans Sten CFO hans.sten@dovregroup.com tel.